Nonlinear time-series analysis of Hyperion's lightcurves

Hyperion is a satellite of Saturn that was predicted to remain in a chaotic rotational state. This was confirmed to some extent by Voyager 2 and Cassini series of images and some ground-based photometric observations. The aim of this aticle is to explore conditions for potential observations to meet in order to estimate a maximal Lyapunov Exponent (mLE), which being positive is an indicator of chaos and allows to characterise it quantitatively. Lightcurves existing in literature as well as numerical simulations are examined using standard tools of theory of chaos. It is found that existing datasets are too short and undersampled to detect a positive mLE, although its presence is not rejected. Analysis of simulated lightcurves leads to an assertion that observations from one site should be performed over a year-long period to detect a positive mLE, if present, in a reliable way. Another approach would be to use 2---3 telescopes spread over the world to have observations distributed more uniformly. This may be achieved without disrupting other observational projects being conducted. The necessity of time-series to be stationary is highly stressed.Comment: 34 pages, 12 figures, 4 tables; v2 after referee report; matches the version accepted in Astrophysics and Space Scienc

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

Subnormal plasma levels of high-density lipoprotein cholesterol (HDL-C) constitute a major cardiovascular risk factor; raising low HDL-C levels may therefore reduce the residual cardiovascular risk that frequently presents in dyslipidaemic subjects despite statin therapy. Cholesteryl ester transfer protein (CETP), a key modulator not only of the intravascular metabolism of HDL and apolipoprotein (apo) A-I but also of triglyceride (TG)-rich particles and low-density lipoprotein (LDL), mediates the transfer of cholesteryl esters from HDL to pro-atherogenic apoB-lipoproteins, with heterotransfer of TG mainly from very low-density lipoprotein to HDL. Cholesteryl ester transfer protein activity is elevated in the dyslipidaemias of metabolic disease involving insulin resistance and moderate to marked hypertriglyceridaemia, and is intimately associated with premature atherosclerosis and high cardiovascular risk. Cholesteryl ester transfer protein inhibition therefore presents a preferential target for elevation of HDL-C and reduction in atherosclerosis. This review appraises recent evidence for a central role of CETP in the action of current lipid-modulating agents with HDL-raising potential, i.e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacological agents under development which directly inhibit CETP. New CETP inhibitors, such as dalcetrapib and anacetrapib, are targeted to normalize HDL/apoA-I levels and anti-atherogenic activities of HDL particles. Further studies of these CETP inhibitors, in particular in long-term, large-scale outcome trials, will provide essential information on their safety and efficacy in reducing residual cardiovascular risk